The Effect of PXR Activation on Blood Pressure Regulation
NCT ID: NCT01690104
Last Updated: 2014-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
22 participants
INTERVENTIONAL
2012-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rifampicin
Rifampicin 600 mg daily
Rifampicin
Placebo
Placebo daily
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifampicin
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 19-30 kg/m2
* Age 18-40 years
* Systolic blood pressure 95 - 140 mmHg
Exclusion Criteria
* Any significant medical condition as judged by the study physician
* Diastolic blood pressure over 90 mmHg
* Sensitivity to rifampicin
* Pregnancy and lactation
* Difficult venipuncture
* Abuse of alcohol or medications, or drug use.
* Participation in other trial with medications in previous 30 days
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oulu University Hospital
OTHER
University of Oulu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janne Hukkanen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Oulu University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oulu University Hospital
Oulu, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rahunen R, Kummu O, Koivukangas V, Hautajarvi H, Hakkola J, Rysa J, Hukkanen J. Pregnane X Receptor-4beta-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension. J Am Heart Assoc. 2022 Mar 15;11(6):e023492. doi: 10.1161/JAHA.121.023492. Epub 2022 Mar 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-005522-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
Rifa-BP
Identifier Type: -
Identifier Source: org_study_id